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Background: In patients with type 2 diabetes, cardiovascular disease (CVD) is the major cause of morbidity and
mortality. We evaluated the combination of NT-proBNP and coronary artery calcium score (CAC) for prediction
of combined fatal and non-fatal CVD and mortality in patients with type 2 diabetes and microalbuminuria
(>30 mg/24-h), but without known coronary artery disease. Moreover, we assessed the predictive value of a
predefined categorisation of patients into a high- and low-risk group at baseline.
Methods: Prospective study including 200 patients. All received intensive multifactorial treatment. Patients with
baseline NT-proBNP >45.2 ng/L and/or CAC ≥400 were stratified as high-risk patients (n = 133). Occurrence of
fatal- and nonfatal CVD (n = 40) and mortality (n = 26), was traced after 6.1 years (median).
Results: High-risk patients had a higher risk of the composite CVD endpoint (adjusted hazard ratio [HR] 10.6
(95 % confidence interval [CI] 2.4-46.3); p = 0.002) and mortality (adjusted HR 5.3 (95 % CI 1.2-24.0); p = 0.032)
compared to low-risk patients. In adjusted continuous analysis, both higher NT-proBNP and CAC were strong
predictors of the composite CVD endpoint and mortality (p ≤ 0.0001). In fully adjusted models mutually including
NT-proBNP and CAC, both risk factors remained associated with risk of CVD and mortality (p ≤ 0.022). There was
no interaction between NT-proBNP and CAC for the examined endpoints (p ≥ 0.31).
Conclusions: In patients with type 2 diabetes and microalbuminuria but without known coronary artery disease,
NT-proBNP and CAC were strongly associated with fatal and nonfatal CVD, as well as with mortality. Their additive
prognostic capability holds promise for identification of patients at high risk.Introduction
In patients with type 2 diabetes, cardiovascular disease
(CVD) is the major cause of morbidity and mortality.
Compared with subjects without diabetes, the risk of
cardiovascular complications is two to four times in-
creased, and is even higher in patients with diabetes and
established albuminuria [1, 2].
Several risk scores have been developed to estimate
the cardiovascular risk in asymptomatic subjects. The
Framingham Risk Score is the most commonly applied* Correspondence: bjos@steno.dk
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unless otherwise stated.global risk score [3]. While proven to be useful to iden-
tify subjects at risk, these scoring models fail to identify
up to 35 % of future CVD. Moreover, as risk scoring
programs are not as predictive in diabetic patients com-
pared to the general population better screening tools
are needed for the latter large patient population [4].
The UKPDS Risk Engine is a type 2 diabetes specific risk
calculator that is probably the most widely used and
which estimates absolute risk of coronary heart disease
or stroke using traditional risk factors plus diabetes-
specific factors including duration of diabetes and HbA1c
[5]. Several studies have examined the validity of theentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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risk equations have been suggested [6, 7].
Brain natriuretic peptide (BNP) and its cleavage prod-
uct N-terminal (NT)-proBNP are secreted in response
to cardiac haemodynamic stress mediated by volume
and pressure overload [8]. BNP exhibits biological activ-
ity while NT-proBNP has none, and when it comes to
analytical methods the in-vitro stability of BNP is assay-
dependent, whereas NT-proBNP is very stable at room
temperature and measurement of NT-proBNP is there-
fore most often used in clinical practice [9].
In a type 2 diabetic population followed for 15 years,
we previously identified plasma NT-proBNP levels as a
powerful predictor of mortality, independent of urinary
albumin excretion rate (UAER) and other risk factors
[10]. Eighty percent of patients in the upper NT-proBNP
tertile (>103 ng/L) died compared to 30 % in the lower
tertile (<41 ng/L; p < 0.001). Other studies have also
shown a strong association of NT-proBNP with vascular
outcomes [11, 12] and mortality [13] in patients with
type 2 diabetes.
The coronary artery calcium score (CAC) is a non-
invasive screening tool derived from a computed tomog-
raphy (CT) scanning [14] that reliably identifies patients
at high risk of future adverse cardiac events [15]. CAC
reflects the global coronary atherosclerotic burden, and
the scoring can be quantified by the Agatston score [16].
Diabetic patients with CAC of 0 have the same risk of
CVD events as people without diabetes [17], and CAC >
400 has been defined as representative of severe coron-
ary artery disease (CAD) with high risk of anatomic cor-
onary stenosis as determined by coronary angiography
(CAG) [18, 19].
To the best of our knowledge, the prognostic value of
a combination of NT-proBNP and CAC has never been
examined in patients with type 2 diabetes. To address
this issue, we evaluate the joint predictive value of NT-
proBNP and CAC for combined fatal and non-fatal
CVD, and all-cause mortality, respectively, in patients
with type 2 diabetes and microalbuminuria, but without
known CAD. Moreover, we evaluate the predictive value
of our predefined categorisation of patients into a high-
and low-risk group at baseline. The pre-specified study
hypothesis was that a screening algorithm based on NT-
proBNP and CAC was able to identify asymptomatic pa-
tients at high risk. Furthermore, analyses of NT-proBNP
and CAC as continuous variables were performed to
support the results of the categorical analyses.
Materials and methods
Participants and study procedure
At Steno Diabetes Center, we identified from January
2007 to February 2008 a cohort of 200 outpatients with
type 2 diabetes treated in a secondary care setting. Allpatients received treatment with intensive multifactorial
intervention constituting of strict glycaemic, lipid and
blood pressure control, as well as antithrombotic therapy
and lifestyle modification according to the Steno-2 study
[20]. Patients were aged between 20 and 70 years, with
the ability to understand and give informed consent. Pa-
tients were included if they met the following inclusion
criteria’s: 1) outpatients with type 2 diabetes defined ac-
cording to WHO criteria’s; 2) no history of CAD or
other cardiac diseases and without any symptoms from
the heart, assessed from patient files and thorough inter-
views and questionnaires; and 3) persistent (two out of
three consecutive measurements) UAER > 30 mg/24 h.
Written invitation was sent to 613 consecutive patients
(69 % males and a mean (standard deviation [SD]) age of
47 (8) years). A total of 72 patients refused to partici-
pate. Furthermore, patients (n = 341) were excluded
(either by phone interview or after examination in the
outpatient clinic) if one or more of the following charac-
teristics were present: 1) normal UAER or non-
persistent elevated UAER (n = 52); 2) symptoms/signs or
history of heart disease including Q waves in 12-lead
ECG (n = 180); 3) relative contraindications to CT angi-
ography (CTA) or CAG, including abnormal plasma
creatinine levels (n = 86); 4) physical or mental disabil-
ity (n = 10); or 5) malignancy (n = 13). Thus, the final
study population included 200 patients. A detailed flow
chart of the selection of the study population is shown
in Fig. 1. The baseline data has previously been pre-
sented [8].
The a priori sample size calculation was based on the
assumption that 20-30 % of the patients would experi-
ence a cardiovascular event during 5 years of follow-up.
The treating physicians were blinded to the predictor
variables NT-proBNP and CAC during the follow-up
period. This study complies with the Declaration of
Helsinki, the research protocol was approved by the
local ethics committee and all patients gave written in-
formed consent.Biochemical analyses and other
NT-proBNP was measured in all patients and analysed by
an immunoassay as previously described [10]. UAER was
measured in 24 h urine collections by an enzyme im-
munoassay [21]. Current smoking was defined as one or
more cigarettes/cigars/pipes a day. The estimated Glom-
erular Filtration Rate (eGFR) was calculated using the
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation [22]. Transthoracic echocardiography
was performed using a Philips IE 33 machine (Phillips
Medical Systems, Best, The Netherlands). Simpson’s apical
biplane method was used to evaluate left ventricle ejection
fraction (LVEF), as previously described [23].
200 type 2 diabetic patients with UAER>30mg/24 h
enrolled and completed the study
Low-risk patients (NT-proBNP≤45.2 ng/L 
and CAC<400), n=67
High-risk patients (NT-proBNP>45.2 ng/L and/or 
CAC≥400), n=133
Patients without significant coronary 
artery disease, n=63
Patients with significant coronary 
artery disease, n=70**
Further cardiovascular imaging*
613 type 2 diabetic patients with 
UAER>30mg/24 h
341 patients excluded due to:
- Normoalbuminuria or non-persistent 
microalbuminuria (n=52)
- Symptoms/signs or history of heart disease 
including Q waves in 12-lead ECG (n=180)
- Contraindications to CT angiography 
including abnormal creatinine (n=86)
- Physical or mental disability (n=10)
- Malignancy (n=13)
72 patients declined participation
During 2007-2008 by phone 
or in the outpatient clinic
Fig. 1 Selection of the study population and algorithm used for risk group assessment with the use of plasma NT-proBNP and coronary artery
calcium score (CAC). * (i) patients with P-NT-proBNP >45.2 ng/L underwent myocardial perfusion imaging. Patients with abnormal myocardial
perfusion imaging (n = 55) or CAC >100 (n =29) were referred for coronary angiography; (ii) patients with P-NT-proBNP ≤ 45.2 ng/L and CAC
400–1000 underwent CT angiography (n = 20); CT angiography was only used in patients with CAC 400–1000 since severe coronary artery
calcifications (CAC > 1000) compromise the validity of CT angiography. Patients with abnormal CT angiography were referred for coronary
angiography (n =15) and (iii) patients with P-NT-proBNP ≤ 45.2 ng/L and CAC >1000 underwent myocardial perfusion imaging (n =9). Patients
with abnormal myocardial perfusion imaging (n = 6) were referred for coronary angiography.**Significant coronary artery disease was defined
as the presence of one or more significant myocardial perfusion defects on myocardial perfusion imaging, and/or one or more significant
major epicardial coronary artery stenosis at coronary angiography
von Scholten et al. Cardiovascular Diabetology  (2015) 14:59 Page 3 of 10Coronary artery calcium score
Determination of CAC was performed during a single
breath hold using a 16 multidetector-row CT scanner
with 3-mm-slice thickness (Philips Precedence MX 8000
IDT 16 slice; Philips Medical Systems, Best, The
Netherlands). Quantification of Agatston CAC [16], in-
cluding intimal and medial calcification in the left main,
left anterior descending artery, circumflex artery and
right coronary artery, was performed on a separate
workstation with dedicated software (Heartbeat-CS,
EBW; Philips Medical Systems) and summed to provide
a total CAC for each participant.
Stratification into risk groups
Patients were stratified into high-risk and low-risk
groups according to CAC and the median NT-proBNP
of the first 50 patients examined in the study [8]: (i) NT-
proBNP >45.2 ng/L = high-risk patients (n = 104); (ii)
NT-proBNP ≤45.2 ng/L and CAC ≥ 400 = high-risk pa-
tients (n = 29) and (iii) NT-proBNP ≤45.2 ng/L andCAC < 400 = low-risk patients (n = 67). High-risk pa-
tients (n = 133) were further examined by myocardial
perfusion scintigraphy imaging (MPI), CTA or CAG ac-
cording to the algorithm shown in Fig. 1, which has pre-
viously been described in details [8]. Based on these
additional examinations, 70 high-risk patients without
any cardiovascular symptoms was exposed to have sig-
nificant CAD, defined as the presence of one or more
significant myocardial perfusion defects on MPI, and/or
one or more significant major epicardial coronary artery
stenosis at CAG, and 63 of the high-risk patients had no
significant CAD.
Follow-up
At 1st of January 2014, we traced all patients through
the Danish National Death Register and the Danish Na-
tional Health Register. For deceased patients, we ob-
tained information on the date and cause of death. All
deaths were classified as CVD unless an unequivocal
non-CVD cause was established. Information about
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tained from the Danish National Health Register.
The predefined primary endpoint was the combination
of cardiovascular mortality, non-fatal myocardial infarc-
tion (ICD-10 codes I20 to I25), stroke (ICD-10 codes
I61or I63), ischaemic cardiovascular disease (ICD-10
codes I70), and heart failure (ICD-10 code I50). For par-
ticipants who experienced multiple endpoints, the ana-
lysis included only the first event.
The secondary endpoint was all-cause mortality. No
participants were lost to follow-up.
Statistical analyses
Logarithmic transformation was performed to achieve
normal distribution for NT-proBNP, CAC and UAER.
All continuous variables are given as medians with inter-
quartile range (IQR) and the categorical variables are re-
ported as total numbers with corresponding percentages.
Differences between groups were calculated using
Mann–Whitney U Test for continuous and χ2 for cat-
egorical variables.
First, we used Kaplan-Meier survival function estimates
and the log-rank test to estimate and compare incidence
rates by risk group. Next, we used Cox proportional haz-
ards analyses to compute hazard ratios (HRs) and 95 %
confidence intervals (CIs) for 1 SD increase of the log
transformed values. We adjusted for sex, age, LDL and
HDL cholesterol, smoking, HbA1c, eGFR, systolic blood
pressure and UAER. In fully adjusted models with known
risk factors for CVD, we additionally included NT-
proBNP and/or CAC. We evaluated the additive vs. syner-
gistic effects of NT-proBNP and CAC on the endpoints
by using appropriate interaction terms and likelihood-
ratio tests. The additive predictive value of both NT-
proBNP and CAC were evaluated with the use of relative
integrated discrimination improvement (rIDI) based on
the Cox models. In addition, the continuous net reclassifi-
cation index (cNRI), with 5 % risk reclassification as cut-
point between models, was calculated based on logistic
models. To facilitate interpretation of the results, we also
computed 5-year absolute risk of the composite CVD end-
point and all-cause mortality associated with CAC at dif-
ferent levels of NT-proBNP from the adjusted Cox
models.
A two-tailed p-value < 0.05 was considered significant.
Statistical analyses were performed using SPSS for Win-
dows, version 20.0 (SPSS, Chicago, IL) and SAS software
(version 9.3 and Enterprise Guide version 5.1; SAS Institute,
Cary, NC).
Results
Patient characteristics and risk groups
The study population (n = 200) included 76 % men, me-
dian (IQR) age was 60 (54–65) years, and median (IQR)of NT-proBNP and CAC was 48.7 (18.6–95.0) ng/L and
183 (6–604), respectively. Table 1 lists clinical character-
istics of all patients and the comparisons between the
high-risk and low-risk group. High-risk patients were
older, had longer known diabetes duration, lower eGFR
and total cholesterol levels, and were more frequently on
beta-blocker treatment than patients classified as low-
risk (p ≤ 0.048).
In addition to oral antidiabetic medications and insulin
most patients were treated with cardiovascular medica-
tions: statins (95 %), aspirin (90 %), renin-angiotensin-
aldosterone system blockade (98 %), diuretics (64 %),
calcium channel blockers (40 %) and beta-blockers
(14 %).
Incidence of endpoints
Median follow-up was 6.4 (range: 5.8-7.2) years for the
survivors, 6.2 (0.8-7.2) years for the patients reaching
the CVD endpoint, and 3.8 (0.3-6.8) years for the non-
survivors. During this period, 40 patients experienced at
least one CVD endpoint and 26 patients died.
Eleven CVD events were fatal and 29 were non-fatal
events leading to hospital admission, including 2 fatal
and 3 non-fatal cases of acute myocardial infarction, 3
non-fatal strokes, 1 fatal and 19 non-fatal cases of is-
chaemic cardiovascular disease, 6 sudden and otherwise
unexplained deaths, and 2 fatal and 4 non-fatal cases of
heart failure. Of the 26 deaths, 10 were CVD-related, 9
were cancer-related and 7 were due to other causes.
Risk prediction in high-risk versus low-risk group
Of the 40 patients with a CVD endpoint, 38 were in the
high-risk and two in the low-risk group. The 26 de-
ceased patients comprised 24 in the high-risk and two in
the low-risk group.
In a Cox regression analysis, patients classified at
high-risk at baseline had a significantly higher risk of the
composite CVD endpoint compared to low-risk patients
(unadjusted HR 11.4 (95 % CI 2.7-47.3); p = 0.001, Fig. 2a;
adjusted HR 11.8 (95 % CI 2.7-52.8); p = 0.002). Simi-
larly, high-risk patients had a significantly higher risk of
all-cause mortality in both unadjusted (HR 6.4 (95 % CI
1.5-27.1); p = 0.012, Fig. 2b) and adjusted (HR 5.9 (95 %
CI 1.3-27.0); p = 0.022) models.
Risk associated with NT-proBNP and CAC in continuous
analyses
In adjusted continuous analysis, higher NT-proBNP was a
strong predictor of the composite CVD endpoint and all-
cause mortality (p ≤ 0.002; Table 2). In the adjusted model
including NT-proBNP, higher age and LDL were also
predictors of the composite CVD endpoint (p ≤ 0.047),
while only smoking was a predictor of all-cause mortality
(p = 0.021).
Table 1 Baseline clinical characteristics of all patients, and low- versus high-risk patients
All patients Low-risk patients High-risk patients p-values
(n = 200) (n = 67) (n = 133)
Male, n (%) 152 (76) 50 (75) 102 (77) 0.75
Age (years) 60 (54–65) 55 (47–61) 62 (59–67) <0.0001
Duration of diabetes (years) 12 (7–18) 8 (4–14) 14 (9–19) <0.0001
Body mass index (kg/m2) 31.4 (28.5-35.6) 31.7 (28.7-35.9) 31 (28–36) 0.66
HbA1c (%) 7.6 (6.9-8.8) 7.9 (7.0-9.0) 7.5 (6.8-8.8) 0.09
HbA1c (mmol/mol) 60 (52–73) 63 (53–75) 69 (51–73) 0.09
UAER (mg/24 h) 103 (39–230) 105 (44–194) 97 (38–97) 0.81
eGFR (CKD-EPI) 91.0 (76.0-102.0) 100.0 (86.0-107.0) 86.0 (74.0-97.5) <0.0001
Systolic blood pressure (mmHg) 129 (118–142) 130 (116–140) 129 (119–142) 0.90
Total cholesterol (mmol/L) 3.8 (3.2-4.5) 4.0 (3.4-4.8) 3.8 (3.1-4.4) 0.048
LDL cholesterol (mmol/L) 1.7 (1.3-2.2) 1.8 (1.2-2.4) 1.7 (1.3-2.1) 0.33
HDL cholesterol (mmol/L) 1.1 (0.9-1.4) 1.1 (1.0-1.3) 1.1 (0.9-1.4) 0.35
Current smoker, n (%) 59 (30) 18 (27) 41 (31) 0.56
Left ventricle ejection fraction (%) 60 (57–63) 60 (57–62) 60 (57–63) 0.33
History of stroke, n (%) 19 (10) 4 (6) 15 (11) 0.19
NT-proBNP (ng/L) 48.7 (18.6–95.0) 15.3 (9.3–26.3) 77.1 (48.7–141.7) -
Coronary artery calcium score 183 (6–604) 7 (0–104) 417 (80–963) -
Treatment with:
Oral antidiabetic, n (%) 170 (85) 57 (85) 113 (85) 0.98
Insulin, n (%) 124 (62) 38 (57) 86 (65) 0.28
RAAS blockade, n (%) 196 (98) 65 (97) 131 (98) 0.48
Statin, n (%) 189 (95) 62 (93) 127 (95) 0.39
Aspirin, n (%) 183 (92) 58 (87) 125 (94) 0.08
Beta-blocker, n (%) 27 (14) 2 (3) 25 (19) 0.002
Calcium channel blockers, n (%) 80 (40) 21 (31) 59 (44) 0.08
Diuretics, n (%) 128 (64) 35 (52) 93 (70) 0.014
High-risk patients = patients with plasma NT-proBNP levels >45.2 ng/L or plasma NT-proBNP levels ≤45.2 ng/L and coronary artery calcium score ≥400, all other
low-risk patients
P-values reflect comparison between high- and low-risk patients
Data are expressed as median (interquartile range) or number of patients (%)
UAER: urinary albumin excretion rate; RAAS: renin-angiotensin-aldosterone system
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strong independent prediction for risk of both the com-
posite CVD endpoint and all-cause mortality (p ≤ 0.006;
Table 2). In the adjusted model including CAC, no other
variables were predictive of the composite CVD end-
point or all-cause mortality (p ≥ 0.12).
Both NT-proBNP and CAC remained significantly as-
sociated with risk of CVD and all-cause mortality in fully
adjusted models mutually including both risk factors
(p ≤ 0.022; Table 2). Addition of the interaction term
between NT-proBNP and CAC was non-significant in
relation to both CVD events (p = 0.90) and all-cause
mortality (p = 0.31).
In adjusted analysis the rIDI for NT-proBNP in rela-
tion to the CVD endpoints was 28.7 % (p = 0.005), and
62.1 % (p = 0.01) for all-cause mortality. In similaranalyses for CAC, the rIDI was 94.4 % (p < 0.0001) for
the CVD endpoints, and 142.5 % (p < 0.0001) for all-
cause mortality. Addition of NT-proBNP to the adjusted
model had significant impact on cNRI for both CVD
endpoints and all-cause mortality (0.36, p = 0.008 and
0.37, p = 0.02; respectively). Addition of CAC to the ad-
justed model had significant impact on CVD endpoints
(0.57, p < 0.0001) and borderline impact on all-cause
mortality (0.29, p = 0.055).
Figure 3 shows the fully adjusted 5-year absolute risk
for CVD endpoints and all-cause mortality according to
NT-proBNP and CAC.
Additional analyses
At baseline, high-risk patients were subdivided into two
groups based on further examinations (Fig. 1): High-risk
Fig. 2 a Kaplan-Meier survival function estimates for risk of combined cardiovascular events by categorisation into low- and high-risk at baseline.
Hazard ratio 11.4 (95 % confidence interval 2.7-47.3); p < 0.0001. b Kaplan-Meier survival function estimates for risk of all-cause mortality by
categorisation into low- and high-risk at baseline. Hazard ratio 6.4 (95 % confidence interval 1.5-27.1); p = 0.004
Table 2 Hazard ratios for a 1 SD increase of the log transformed values of NT-proBNP and coronary artery calcium score for fatal
and nonfatal cardiovascular events and all-cause mortality
Label Cardiovascular events All-cause mortality
Number of events (%) 40 (20) 26 (13)
NT-proBNP Unadjusted 1.9 (1.4–2.7)c 2.2 (1.4–3.4)c
Adjusted 1.9 (1.3–2.7)b 2.2 (1.4–3.6)b
Fully adjusted 1.7 (1.1–2.5)a 1.9 (1.2-3.2)a
Coronary artery calcium score Unadjusted 3.6 (2.0–6.4)c 3.4 (1.7–6.8)c
Adjusted 3.7 (1.9–7.4)c 2.9 (1.4–6.3)b
Fully adjusted 3.4 (1.7–6.7)c 2.6 (1.2–5.6)b
Values are hazard ratios (95 % confidence intervals) and represent a 1 SD increase of the log transformed values of NT-proBNP and coronary artery calcium score
Adjusted models include sex, age, LDL and HDL cholesterol, smoking, HbA1c, eGFR, systolic blood pressure and urinary albumin excretion rate. Fully adjusted
models additionally include coronary artery calcium score and NT-proBNP mutually
Significance of the hazard ratios: aP < 0.05, bP <0.01, cP <0.0001
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Fig. 3 The continuous risk functions cover the 5th to 95th percentile interval of the coronary artery calcium score and correspond to levels of
NT-proBNP at 7, 20, 55, 148, 403 ng/L (approximate the 5th, 25th, 50th, 75th and 95th percentiles of the distribution). Risk functions were fitted
by Cox regression with adjustment for sex, age, smoking, LDL and HDL cholesterol, HbA1c, eGFR, systolic blood pressure and urinary albumin
excretion rate at baseline
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tients without CAD (n = 63). In additional analyses com-
paring each of these two high-risk groups to the low-risk
group, both high-risk groups had an elevated risk of the
composite CVD endpoint (adjusted HR ≥4.0; p ≤ 0.025),
while risk of all-cause mortality was only elevated for
the high-risk patients without CAD compared to low-
risk patients (adjusted HR 7.7; p = 0.022).
When comparing the two high-risk groups, the high-
risk patients with CAD at baseline had an elevated risk
of the composite CVD endpoint compared with
the high-risk patients without CAD (adjusted HR 2.8;
p = 0.012). However, the risk of all-cause mortality
was comparable between the two high-risk groups
(p = 0.55).
In analyses including all 200 patients, additionally in-
clusion of LVEF in the adjusted models revealed that
both NT-proBNP (adjusted HR 1.6; p = 0.027) and CAC
(adjusted HR 3.3; p = 0.001) remained predictive of
CVD endpoints. Similarly, both NT-proBNP (adjusted
HR 1.8; p = 0.026) and CAC remained predictors of
all-cause mortality (adjusted HR 2.9; p = 0.013). In nei-
ther of these models, LVEF was a significant predictor
(p ≥ 0.08).
Similar models including history of stroke (n = 19) in
the multivariate adjustment, revealed that NT-proBNP
(adjusted HR 1.7; p = 0.017) and CAC (adjusted HR 2.9;
p = 0.02) remained predictive of CVD endpoints. Also
for all-cause mortality, both NT-proBNP (adjusted HR
2.2; p = 0.001) and CAC (adjusted HR 3.0; p = 0.009)
remained predictive. History of stroke was a predictor of
CVD endpoints (HR 3.3; p = 0.017), but not of all-cause
mortality (p > 0.27).Discussion
In this prospective study of asymptomatic patients with
type 2 diabetes and microalbuminuria, without known
CAD, risk stratification with NT-proBNP and CAC,
alone and in combination, predicted CVD and all-cause
mortality on top of established risk factors. According to
our previously defined risk criteria based on NT-
proBNP and CAC, 24 of 26 deaths occurred in the high
risk group during 6.1 years of follow-up and in these pa-
tients the adjusted HR for fatal or nonfatal CVD was
10.6 (95 % CI 2.4-46.3). Both risk markers added inde-
pendent predictive value in the assessment of risk for fu-
ture events. Identifying diabetic subjects at risk of CVD
and death at an early stage and initiating more aggres-
sive therapy in these individuals could improve outcome.
We demonstrated that patients stratified into a high-
risk group (NT-proBNP ≥45.2 ng/L and/or CAC ≥ 400)
had a significantly higher risk of CVD events and mor-
tality compared to low-risk patients. Findings were simi-
lar when comparing each of the high-risk groups with
the low-risk group. When comparing the high-risk pa-
tients with significant CAD with the high-risk group
without CAD, the former had a higher risk of CVD
endpoints, while there was no difference in all-cause
mortality between these groups (presumably explained
by the high fraction of cancer-related deaths). Patients
stratified as low-risk had a strikingly low rate of CVD
and fatalities.
In patients with type 2 diabetes, elevated UAER is con-
sidered to be the most consistent independent predictor
of adverse outcomes [24]. Indeed, in more recent pro-
spective studies in patients with type 2 diabetes, NT-
proBNP has been reported to be a strong and independent
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addition, NT-proBNP has been shown to be a strong risk
predictor of CVD events in patients with stable CVD [26].
In agreement with this contention, our study showed that
higher NT-proBNP was predictive of CVD and mortality
even after adjustment for CAC and traditional CVD risk
factors.
With regard to CAC, several studies in patients with
type 2 diabetes have demonstrated CAC to be a useful risk
marker for CVD events and mortality [15, 27–31]. An
extensive high CAC (>600) has been shown to be related
to high risk of developing chronic CAD-related events;
whereas acute CAD-related events mainly occurred in
subjects with mild and moderate CAC score (1–600) [32].
These findings were confirmed in our study in patients
with albuminuria, where a higher CAC was associated
with increased risk of CVD events and mortality even in
fully adjusted models.
While CAC is strongly correlated with a patient’s
underlying coronary atherosclerotic plaque burden, high
levels of NT-proBNP are associated with depressed
systolic function and diastolic dysfunction. Thus, NT-
proBNP may provide unique risk information beyond
the extent of coronary atherosclerosis defined by CAC,
which indeed was the rationale of our risk stratification
model performed at baseline. After 6 years of follow-up,
we found this model to be very potent for prediction of
CVD and mortality. The combination of the two mea-
sures has previously been investigated in two large co-
horts of non-diabetic subjects and here demonstrated
improved risk prediction for CVD and mortality in com-
parison to traditional cardiovascular risk factors [33, 34].
However, to our knowledge, we are the first to investi-
gate the combined prognostic effect of NT-proBNP and
CAC in patients with type 2 diabetes and we demon-
strated an additive effect of these two risk factors.
Therefore, we consider the combination of NT-proBNP
and CAC to provide unique risk information in asymp-
tomatic subjects with type 2 diabetes. The usual risk
stratification measures in symptomatic patients consists
of a combination of echocardiography and CAG, while
our stratification model provided prognostic information
for asymptomatic patients, but non-invasively and at a
much lower cost. Although the identification of asymp-
tomatic patients with type 2 diabetes at high risk of ad-
verse outcomes may be accomplished by our simple
screening algorithm, a major concern is how to elimin-
ate or at least minimize the high risk burden. Accord-
ingly, it remains to be proven that implementation of
more aggressive medical management in these patients
with elevated NT-proBNP and/or CAC improves clinical
outcome. However, a randomized controlled study in
300 patients with type 2 diabetes and elevated NT-
proBNP (>125 pg/ml) demonstrated that accelerated up-titration of renin-angiotensin-aldosterone system- and
beta-blockers to maximum tolerated dosages was an ef-
fective and safe intervention for the primary prevention
of CVD events. The study did not document a decrease
in NT-proBNP concentrations in the treatment group
[35]. Treatment of patients with increased CAC scores
with lipid-lowering drugs has also been shown to reduce
subsequent CVD [36], while another study did not find
intensive lipid-lowering treatment to prevent progres-
sion of CAC [37]. Thus, more intervention studies are
needed in order to clarify therapies with best impact to
decrease/prevent CVD. While the optimal medical strat-
egy is not yet fully elucidated in these high-risk patients,
it is tempting to speculate that early invasive therapy
with CAG and coronary revascularization would be use-
ful. However, the effect of coronary revascularization in
asymptomatic patients is controversial and such proce-
dures are currently not recommended [38].
It should be acknowledged that assessment of NT-
proBNP is feasible using a simple blood test, while quan-
tification of CAC requires CT imaging, which includes
radiation exposure to the patient and is of much higher
cost. Therefore, selection of subjects for CT imaging
should be performed carefully, albeit that this examin-
ation is rapid (<5 min) and the radiation dose is low
(1.5 mSv) compared to, e.g. CTA (12 mSv). These cost
and safety issues underscore the need for further investi-
gations to maximize potential benefits of screening algo-
rithms and aggressive therapy in high-risk patients.
Given that multifactorial treatment is already applied,
this algorithm provides prognostic information, but can-
not guide additional treatment decisions. For a patient
where multifactorial intervention is not initiated the al-
gorithm would strengthen the recommendation for such
intervention. New intervention studies are needed to
clarify additional treatment options to mitigate the in-
creased risk of CVD and mortality in type 2 diabetes.
Considerations might include new therapeutic options,
lower targets or increased doses of already applied
treatments.
Strengths and limitations
Even though a limitation of our study is the relatively low
number of patients and consequent limited amount of
study endpoints making the conclusions not very robust,
we found our risk stratification model to be very efficient
for identification of subjects at risk of CVD. Out of 40
fatal and nonfatal CVD endpoints, only two low-risk pa-
tients experienced an event, which was nonfatal in both
cases, and only two low-risk patients died during six years
of follow-up, both from non-cardiovascular causes. Our
initial division of the study cohort into high- or low risk
patients might have provided changes in treatment and
intervention, and therefore the estimate of risk in the
von Scholten et al. Cardiovascular Diabetology  (2015) 14:59 Page 9 of 10high-risk group is likely to be conservative. However, des-
pite this, risk was still elevated in the high-risk group. The
strength of the study is the prospective design and inclu-
sion of asymptomatic patients with type 2 diabetes and
microalbuminuria, which is an established predictor of ad-
verse outcome.
Conclusion
In asymptomatic patients with type 2 diabetes and micro-
albuminuria without known CAD, risk stratification with
NT-proBNP and CAC was strongly associated with fatal
and nonfatal CVD, and all-cause mortality, respectively.
While both NT-proBNP and CAC were strong risk fac-
tors, their additive prognostic effect holds promise for
identification of patients at high-risk.
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